4CPS-105 Cardiovascular risk factors in patients with HIV infection with antiretroviral treatment

• Published in: European journal of hospital pharmacy. Science and practice 2022-03, Vol.29 (Suppl 1), p.A187-A187
• Main Authors: Fernández González, A, Aparicio Carreño, C, Gándara Ande, A, Fórneas Sangil, A, Fuertes Camporro, S, Fra Yañez, J
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; AIDS; Antiretroviral drugs; Conflicts of interest; Diabetes; Gender; HIV; Human immunodeficiency virus; Hypertension; Infections; Risk factors; Section 7: Post Congress additions
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2022-eahp.393

Background and importanceCardiovascular disease (CVD) is a major cause of morbidity and mortality in HIV patients. Recent studies suggest that the increased incidence of CVD is due to increased patient longevity, chronic inflammation and immune activation associated with HIV infection and antiretroviral therapy (ART) itself, which may contribute to increased cardiovascular risk (CVR).Aim and objectivesTo establish the frequency of cardiovascular risk factors (CVRF), as well as to estimate the incidence of CVR in patients with HIV.Material and methodsObservational, retrospective study with all HIV patients with ART who were followed up by the Infectious Diseases Unit during 2020 at the Outpatient Unit.The role of the hospital pharmacist in the treatment of these patients is the prevention, identification and management of the side effects associated with ART.The variables gathered were: age, gender, AIDS prevalence, time since diagnosis, time and current ART.The CVRF were evaluated following the criteria of the European Society of Cardiology: age, male gender, smoking, hypertension, diabetes, dyslipidaemia, obesity.The Framingham scale adapted to the HIV population was used to determine the risk of CVD at 10 years: low risk (45 years 78.5%, smoking 44%, hypertension 26.3%, diabetes 18.1%, HDL-cholesterol (HDL-C 240 mg/dL) 10.8% and obesity 15.1%. There was a higher prevalence of CVRF associated with the male gender, which was statistically significant in diabetes, lower HDL-C and higher triglycerides (p